Stanford U. is starting a program to advocate against the influence of drug and medical device cies. on physicians, a practice that spins some US$1 billion per year. The problem is that the program is being partly funded by Pfizer. Stanford claims that Pfizer’s support was 100% voluntary and that there are no strings attached. How far can we push the boundaries on conflicts of interest? And if it appears conflicted, doesn’t it defeat the purpose from the get-go?
Sometimes we’ll publish “older” stuff as part of what we like to call “weekend catch-up reading”. This time it’s a Fortune Magazine interview with Joel I. Klen, New York City’s school chancellor and former CEO of Bertelsmann’s USA operations. He’s best know as the Dept. of Justice’s anti-trust czar that sued Microsoft, so it’s telling [...]